scPharmaceuticals Q4 2022 Earnings Report
Key Takeaways
scPharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2022 and ended the quarter with $118.4 million in cash, cash equivalents, restricted cash and investments. The company commenced the launch and commercial availability of FUROSCIX in February 2023.
Launched and commenced commercial availability of FUROSCIX on February 20, 2023.
Ended Q4 with cash, cash equivalents, restricted cash and investments of $118.4M.
Further strengthened balance sheet through $50 million underwritten offering of common stock in November 2022.
Entered into $100 million secured debt financing agreement with funds managed by Oaktree Capital Management in October 2022.
scPharmaceuticals
scPharmaceuticals
Forward Guidance
Based on its current operating plan, the Company expects its operating costs to increase in 2023 as it supports the launch of FUROSCIX, including investments in marketing and a field sales force.